In addition, an anti-IL-6 monoclonal antibody, CNTO328, was tested based on the report demonstrating that the IL-6/TGF-β axis is critical for EGFR-TKI-resistant H1650 NSCLC cells with EMT phenotype [8]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.